Startup Virta Health saw 60% revenue growth last year, topping $100 million, driven by demand for its employer weight loss ...

Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a fair price target of $1,200. See more.

LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...

Hims has become a leader in the weight loss treatment industry by offering access to men’s health solutions that are both ...

"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Dr. Mehmet Furkan Burak said people who have lost weight and then gained it again can feel guilt or shame and blame ...

Metsera has linked its GLP-1 drug candidate to weight loss of up to 11.3% after 12 weeks, encouraging the biotech to use some ...